title: Qualitative and quantitative changes in saliva among patients with thyroid dysfunction prior to and following the treatment of the dysfunction.
abstract: OBJECTIVE
  Animal studies have shown thyroid dysfunction affects salivary gland functioning, however conclusive human studies are lacking. We sought to assess the qualitative and quantitative changes in saliva among subjects with thyroid dysfunction prior to and following treatment.
  
  
  METHODS
  A longitudinal observational study of 153 newly diagnosed subjects who had hypothyroidism (n = 107) or hyperthyroidism (n = 46), aged 18-45 years, fulfilling the inclusion/exclusion criteria was conducted. Analysis of salivary parameters (stimulated salivary flow rate (SSFR), pH and buffering capacity) was performed at diagnosis (baseline), on attaining euthyroid state and 3 months thereafter.
  
  
  RESULTS
  Subjects were 86% females, and at baseline 13% of subjects had hyposalivation. Mean SSFR, pH, buffering capacity as well as percentage of hypothyroid subjects having normal salivation increased following thyroid treatment.
  
  
  CONCLUSIONS
  Thyroid dysfunction affects salivary gland function. Subjects with chronic hyposalivation should have thyroid function assessment if the known established causes are excluded.
authors: Department of Public Health Dentistry, Narayana Dental College & Hospital, Chinthareddypalem, Nellore, Andhra Pradesh 524002, India. kappoordhanya@hotmail.com
authors: Dhanya
authors: D
authors: Muralidharan
authors: Nusrath
authors: N
authors: Fareed
authors: P V
authors: PV
authors: Pradeep
authors: Shanthi
authors: S
authors: Margabandhu
authors: K
authors: K
authors: Ramalingam
authors: B V
authors: BV
authors: Ajith Kumar
mesh_terms: D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000097:blood; D013956:Antithyroid Agents / Q000627:therapeutic use; D001324:Autoantigens / Q000276:immunology; D002021:Buffers; D002231:Carbimazole / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006980:Hyperthyroidism / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D007037:Hypothyroidism / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D018828:Immunoglobulins, Thyroid-Stimulating / Q000097:blood; D007453:Iodide Peroxidase / Q000276:immunology; D033862:Iron-Binding Proteins / Q000276:immunology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011989:Receptors, Thyrotropin / Q000097:blood; D012463:Saliva / Q000378:metabolism / Q000502:physiology*; D012469:Salivary Glands / Q000378:metabolism / Q000503:physiopathology; D012636:Secretory Rate / Q000502:physiology; D013954:Thyroglobulin / Q000276:immunology; D013970:Thyronines / Q000097:blood; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000627:therapeutic use; D014284:Triiodothyronine / Q000097:blood; D014987:Xerostomia / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D055815:Young Adult
chemical_list: D000906:Antibodies; D013956:Antithyroid Agents; D001324:Autoantigens; D002021:Buffers; D018828:Immunoglobulins, Thyroid-Stimulating; D033862:Iron-Binding Proteins; D011989:Receptors, Thyrotropin; D013970:Thyronines; C094372:thyrotropin-binding inhibitory immunoglobulin; D014284:Triiodothyronine; D002231:Carbimazole; D013972:Thyrotropin; D013954:Thyroglobulin; C056658:TPO protein, human; D007453:Iodide Peroxidase; D013974:Thyroxine